25 Nov
25Nov

Pharma major Lupin Limited announced the launch of tacrolimus capsules USP, 0.5 mg, 1 mg, and 5 mg, after Lupin’s alliance partner Concord Biotech Limited (Concord) received an approval for its ANDA from the United States Food and Drug Administration (FDA).

Tacrolimus capsules USP, 0.5 mg, 1 mg, and 5 mg, are the generic equivalent of Prograf capsules, 0.5 mg, 1 mg, and 5 mg, of Astellas Pharma US, Inc., and are indicated for the prophylaxis of organ rejection, in adult patients receiving allogeneic kidney transplant, liver transplant, and heart transplant, and in pediatric patients receiving allogeneic liver transplants, in combination with other immunosuppressants.

Tacrolimus capsules USP, 0.5 mg, 1 mg, and 5 mg had an annual sales of approximately US$ 303 million in the US, as per IQVIA MAT September 2020.

 Source : Pharmabiz

Comments
* The email will not be published on the website.